Pegfilgrastim clinical trials
Also written Neulasta, DA-3031 and CHS-1701.
How each study uses pegfilgrastim is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the pegfilgrastim studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 31 Jan 2002 · NEULASTA · BLA 125031 (FDA, Drugs@FDA)
- European Union
- 22 Aug 2002 · Neulasta · EMEA/H/C/000420 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
132 studies that test it; most in 2003 (13)
| Year | Studies |
|---|---|
| 2000 | 3 |
| 2001 | 4 |
| 2002 | 6 |
| 2003 | 13 |
| 2004 | 3 |
| 2005 | 7 |
| 2006 | 9 |
| 2007 | 5 |
| 2008 | 9 |
| 2009 | 1 |
| 2010 | 3 |
| 2011 | 1 |
| 2012 | 8 |
| 2013 | 3 |
| 2014 | 4 |
| 2015 | 10 |
| 2016 | 8 |
| 2017 | 12 |
| 2018 | 4 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 5 |
| 2022 | 5 |
| 2024 | 3 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 57 · Other 79
Amgen (15) · M.D. Anderson Cancer Center (7) · Memorial Sloan Kettering Cancer Center (4) · Pfizer (4) · Gynecologic Oncology Group (4) · National Cancer Institute (NCI) (3) · Kyowa Kirin Co., Ltd. (3) · Spectrum Pharmaceuticals, Inc (3)
Often tested with
Tested in the same studies.
Filgrastim (15) · Docetaxel (14) · Cyclophosphamide (11) · Cisplatin (10) · Doxorubicin (9) · Carboplatin (9) · Etoposide (8) · Paclitaxel (8)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Pegfilgrastim is the comparator. A study of two new drugs counts under both.
- 1NPI 2358 · BeyondSpring Pharmaceuticals Inc.
Reaching primary completion within a year · 7, 3 in phase 3
Studies that test pegfilgrastim, phase 3 first.
- Dec 2026Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma PatientsPhase 3 · The Affiliated People's Hospital of Ningbo University
- Jun 2027Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell LymphomaPhase 3 · National Cancer Institute (NCI)
- Sep 2027Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract CancerPhase 2/3 · National Cancer Institute (NCI)
- Jan 2027Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast CancerPhase 2 · Centre Leon Berard
- Apr 2027High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin LymphomaPhase 1 · Memorial Sloan Kettering Cancer Center
- Jun 2027Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast CancerPhase 2 · Yeon Hee Park
- Sep 2027Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.Phase 1 · Memorial Sloan Kettering Cancer Center
Studies
Open first, then newest update. How each study uses pegfilgrastim is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 136
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract CancerRecruitingPhase 2/3National Cancer Institute (NCI)NCT04628767Written as Pegfilgrastim
- Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed MedulloblastomaRecruitingPhase 2St. Jude Children's Research HospitalNCT05535166Written as Pegfilgrastim
- Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell TumoursRecruitingPhase 3University of SydneyNCT02582697Written as Pegylated G-CSF (Pegfilgrastim)
- Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic SyndromeRecruitingPhase 2M.D. Anderson Cancer CenterNCT01624805Written as Pegfilgrastim
- An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant TherapyRecruitingNot applicableYonsei UniversityNCT07525869Written as Pegfilgrastim (Neulasta)
- Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast CancerRecruitingPhase 2Yeon Hee ParkNCT06616987Written as Sacituzumab Govitecan with pegfilgrastim
- Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary CancersRecruitingPhase 2National Cancer Center, KoreaNCT06135896Written as Tripegfilgrastim
- Compare the Efficacy and Safety of QL0605 Injections at Different TimepointsRecruitingPhase 4Qilu Pharmaceutical Co., Ltd.NCT06616571Written as QL0605(PEG-rhG-CSF)
- Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma PatientsRecruitingPhase 3The Affiliated People's Hospital of Ningbo UniversityNCT06520176Written as Pegfilgrastim
- The Neuroprotective Effect of PEG-GCSF in the Traumatic Optic NeuropathyRecruitingEarly Phase 1Buddhist Tzu Chi General HospitalNCT06168188Written as Neulasta® (pegfilgrastim)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell LymphomaActive, not recruitingPhase 3National Cancer Institute (NCI)NCT04759586Written as Pegfilgrastim
- Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.Active, not recruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT02909036Written as Pegfilgrastim
- Split-Dose R-CHOP for Older Adults With DLBCLActive, not recruitingPhase 2University of Wisconsin, MadisonNCT03943901Written as Pegfilgrastim
- High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin LymphomaActive, not recruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT01840566Written as Pegfilgrastim
- NEO-adjuvant Chemo-immunotherapy in Pancreatic CancerActive, not recruitingPhase 2Australasian Gastro-Intestinal Trials GroupNCT06094140Written as Pegylated G-CSF
- Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast CancerActive, not recruitingPhase 3IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, ItalyNCT00433420Written as pegfilgrastim
- Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast CancerCompletedPhase 1/2NCIC Clinical Trials GroupNCT00066443Written as pegfilgrastim
- Evaluation and Modeling of the Effect of G-CSF on the Evolution of Polynuclear Neutrophils During Dense Dose Epirubicin-Cyclophosphamide RegenerationCompletedNot applicableCentre Georges Francois LeclercNCT05296317Written as Dense dose epirubicin-cyclophosphamide chemotherapy with administration of peg-G-CSF (pegfilgrastim)
- Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast CancerActive, not recruitingPhase 2Centre Leon BerardNCT03571633Written as Pegfilgrastim
- A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant ChemotherapyCompletedPhase 4Ottawa Hospital Research InstituteNCT04781959Written as Pegfilgrastim
See all 136 studies that test pegfilgrastim →
Given beside what is tested · 123 — pegfilgrastim is usual care or a partner of the new treatment
- Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk DiseaseRecruitingPhase 2St. Jude Children's Research HospitalNCT06023641Written as Filgrastim, peg-filgrastim
- Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell LymphomasRecruitingPhase 1City of Hope Medical CenterNCT07278856Written as Pegfilgrastim
- Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal AdenocarcinomaNot yet recruitingPhase 2Abramson Cancer Center at Penn MedicineNCT07059611Written as Pegfilgrastim
- Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric GliomaNot yet recruitingPhase 2St. Jude Children's Research HospitalNCT07916389Written as Pegfilgrastim
- Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS TumorsRecruitingPhase 2St. Jude Children's Research HospitalNCT06528691Written as Pegfilgrastim
- Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid LeukemiaRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT03214562Written as Pegfilgrastim
- ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin LymphomaRecruitingPhase 2Michael Spinner, MDNCT07021989Written as Pegfilgrastim
- A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCTRecruitingPhase 2Children's Oncology GroupNCT04684368Written as Pegfilgrastim
- Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT05645718Written as Pegfilgrastim
- Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell LymphomaRecruitingPhase 3Stichting Hemato-Oncologie voor Volwassenen NederlandNCT06220032Written as Pegfilgrastim
- Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/LymphomaRecruitingPhase 2University of WashingtonNCT07224100Written as Pegfilgrastim
- Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT03136146Written as Pegfilgrastim
- Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced MalignanciesRecruitingPhase 1/2University of California, IrvineNCT07064018Written as Pegfilgrastim
- Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory SarcomasRecruitingPhase 1/2David S Shulman, MDNCT06709495Written as Pegfilgrastim
- CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.RecruitingPhase 2TORL Biotherapeutics, LLCNCT06690775Written as Pegfilgrastim (drug)
- Mozobil for Autologous Hematopoietic Stem Cell TransplantationRecruitingPhase 2Thomas Jefferson UniversityNCT07188090Written as Gcsf
- Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell LymphomasActive, not recruitingPhase 1National Cancer Institute (NCI)NCT03220022Written as Pegfilgrastim
- Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin LymphomaActive, not recruitingPhase 3National Cancer Institute (NCI)NCT03907488Written as Pegfilgrastim
- Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by SurgeryActive, not recruitingPhase 2National Cancer Institute (NCI)NCT00334815Written as Pegfilgrastim
- FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate CancerActive, not recruitingPhase 1/2Rahul AggarwalNCT05011188Written as Pegfilgrastim
Showing 20 of 123.
As the comparator · 16 — what is tested is compared with pegfilgrastim
- A Phase I PK/PD Study of PEG-MetHuG-CSF (P2203) in Healthy VolunteersCompletedPhase 1PharmaEssentiaNCT06698861Written as Neulasta (Amgen)
- Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3CompletedPhase 3BeyondSpring Pharmaceuticals Inc.NCT03102606Written as Pegfilgrastim
- Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2CompletedPhase 2BeyondSpring Pharmaceuticals Inc.NCT04345900Written as Pegfilgrastim
- Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/DocetaxelCompletedPhase 2/3Teva Branded Pharmaceutical Products R&D, Inc.NCT00837265Written as Pegfilgrastim
- Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic ChemotherapyCompletedPhase 3EVIVE BiotechnologyNCT03252431Written as Neulasta
- Neugranin in Breast Cancer Participants Receiving Doxorubicin/DocetaxelCompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT01126190Written as Pegfilgrastim
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast CancerCompletedPhase 3NSABP Foundation IncNCT00887536Written as pegfilgrastim
- Efficacy and Safety Study With MYL-1401H and NeulastaCompletedPhase 3Mylan Inc.NCT02467868Written as Neulasta
- Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's LymphomaCompletedPhase 3Alliance for Clinical Trials in OncologyNCT00118209Written as pegfilgrastim
- Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial CancerCompletedPhase 3GOG FoundationNCT00063999Written as Pegfilgrastim
- Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced NeutropeniaActive, not recruitingPhase 3BeyondSpring Pharmaceuticals Inc.NCT03294577Written as Pegfilgrastim
- Intermittent G-CSF in Patients With Breast Cancer Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)TerminatedPhase 2Asan Medical CenterNCT02685111Written as Peg-filgrastim
- Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced NeutropeniaTerminatedPhase 2Prolong PharmaceuticalsNCT03559387Written as Neulasta®
- Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic ChemotherapyCompletedPhase 2EVIVE BiotechnologyNCT01648322Written as Neulasta® (pegfilgrastim)
- Trial to Compare the Efficacy and Safety of Pegfilgrastim Biosimilar in Subjects With High Risk Stage Breast Cancer Receiving ChemotherapyWithdrawnPhase 3Eurofarma Laboratorios S.A.NCT02768714Written as Neulastim
- Pharmacokinetic/Pharmacodynamic (PK/PD) Study Evaluating Pegfilgrastim Hospira Compared to Neulasta (Amgen) in Healthy VolunteersCompletedPhase 1Hospira, now a wholly owned subsidiary of PfizerNCT00938678Written as Neulasta (Amgen)
Codes
What other systems call pegfilgrastim · ClinicalTrials.gg INT004446
- MeSH (NLM) C455861pegfilgrastimConfirmed NLM, Wikidata
- UNII (FDA) 3A58010674PEGFILGRASTIMConfirmed FDA, NLM, Wikidata
- RxNorm 338036Confirmed FDA, Wikidata
- Wikidata Q1592932pegfilgrastimConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1854PegfilgrastimConfirmed FDA, Wikidata
- DrugBank DB00019One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C455861 | pegfilgrastim | Confirmed NLM, Wikidata |
| UNII (FDA) | 3A58010674 | PEGFILGRASTIM | Confirmed FDA, NLM, Wikidata |
| RxNorm | 338036 | — | Confirmed FDA, Wikidata |
| Wikidata | Q1592932 | pegfilgrastim | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1854 | Pegfilgrastim | Confirmed FDA, Wikidata |
| DrugBank | DB00019 | — | One source Wikidata |
Also registered as lipegfilgrastim (UNII 4AWF0N6QV3 · RxNorm 1440046).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.